BMO Capital Downgrades Synta Pharma. (SNTA) to Underperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to BMO Capital Downgrades Synta Pharma. (SNTA) to Underperform
March 12, 2014 7:46 AM EDT
Stifel Nicolaus downgraded Synta Pharma. (NASDAQ: SNTA) from Hold to Sell.
For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.
Shares of Synta Pharma. closed at $5.28 yesterday, with a 52 week range of $3.70-$11.88.... More
March 11, 2014 7:05 AM EDT
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) and QuantumLeap Healthcare Collaborative announced that Syntas lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2). I-SPY 2 is a standing phase 2 randomized, controlled, multicenter trial for women with newly diagnosed, locally advanced breast cancer (Stage 2 or higher) that is designed to test whether adding investigational drugs to standard chemotherapy is better than standard chemotherapy alone in the neo-adjuvant setting (prior to surgery).
The I-SPY 2 TRIAL... More
March 11, 2014 6:33 AM EDT
Synta Pharmaceuticals, Inc. (NASDAQ: SNTA) reported Q4 EPS of ($0.31), which may not compare with the analyst estimate of ($0.30).
For earnings history and earnings-related data on Synta Pharmaceuticals, Inc. (SNTA) click here.... More
